[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100658376":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":20,"studyPopulation":13,"armGroups":21,"interventions":28,"overallOfficials":34,"centralContacts":38,"locations":47,"responsibleParty":64,"collaborators":66,"id":70,"slug":71,"hasResults":72,"nctId":73,"briefTitle":74,"officialTitle":74,"acronym":13,"eligibilityCriteria":75,"healthyVolunteers":72,"sex":76,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":13,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":90,"whyStopped":13,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"Johns Hopkins University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"Glutamate levels (a.u.)","brain chemistry (e.g. glutamate levels in the prefrontal cortex) measured by Magnetic Resonance Spectroscopy (MRS)","one MRS scan on the same day of drug administration (acute effect)",null,{"allocation":15,"interventionModel":16,"interventionModelDescription":13,"primaryPurpose":17,"observationalModel":13,"timePerspective":13,"maskingInfo":18},"NA","SINGLE_GROUP","BASIC_SCIENCE",{"masking":19,"maskingDescription":13,"whoMasked":13},"NONE","Many symptomatic domains in schizophrenia, with the exception of positive symptoms, are inadequately addressed by currently available antipsychotics, all of which rely on dopamine D2 receptor blockade. This blockade also elicits several major side effects. Conversely, some atypical antipsychotics possess additional receptor-binding capacities (e.g., targeting 5-HT2A and 5-HT7 receptors) and exhibit some efficacy against non-positive symptoms, such as cognitive dysfunction. Focusing on these clinico-pharmacological features, DSP has developed a novel compound that selectively binds to 5-HT2A and 5-HT7 receptors without interacting with the D2 receptor. This compound has been tested at the clinical level at a single dose, which was formally approved. Thus, the investigators plan to evaluate the neural effects of a single oral dose of DSP-2342 on brain chemistry and brain activity in adults with schizophrenia. Guided by preclinical data for DSP-2342, the investigators will measure brain chemistry using magnetic resonance spectroscopy (MRS) and brain activity via task-based functional MRI (fMRI), comparing these measures before and after a single dose of DSP-2342. Based on these preclinical findings, the investigators hypothesize that DSP-2342 will produce measurable changes in brain chemistry, such as altering glutamate levels in the prefrontal cortex.",[22],{"label":23,"type":24,"description":25,"interventionNames":26},"Evaluation of the neural effects of a single oral dose of DSP-2342","EXPERIMENTAL","The primary goal of this study is to evaluate the neural effects of a single oral dose of DSP-2342 on brain chemistry and brain activity in adults with schizophrenia. The investigators will measure brain chemistry using magnetic resonance spectroscopy and brain activity using task-based functional MRI. The investigators will compare these measures before and after a single dose of DSP-2342.",[27],"Drug: DSP-2342",[29],{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":13},"DRUG","DSP-2342","a single oral dose of DSP-2342 on brain chemistry and brain activity in adults with schizophrenia.",[23],[35],{"name":36,"affiliation":5,"role":37},"Akira Sawa, MD","PRINCIPAL_INVESTIGATOR",[39,43],{"name":36,"role":40,"phone":41,"phoneExt":13,"email":42},"CONTACT","443-846-1409","asawa1@jhmi.edu",{"name":44,"role":40,"phone":45,"phoneExt":13,"email":46},"Kristin Bigos, PhD","412-480-3933","kbigos1@jhu.edu",[48],{"facility":49,"status":13,"city":50,"state":51,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"johns Hopkins University","Baltimore","Maryland","21287","United States","US",{"type":56,"coordinates":57},"Point",[58,59],-76.61219,39.29038,{"lat":59,"lon":58},[62],{"name":63,"role":40,"phone":41,"phoneExt":13,"email":42},"akira sawa, professor,, MD",{"type":65,"investigatorFullName":13,"investigatorTitle":13,"investigatorAffiliation":13,"oldNameTitle":13,"oldOrganization":13},"SPONSOR",[67],{"name":68,"class":69},"Sumitomo Pharmaceuticals America","INDUSTRY","100658376","phase-2-brain-imaging-of-dsp-2342-100658376",false,"NCT07850102","Brain Imaging of DSP-2342","Inclusion Criteria:\n\n* right-handed, participants with schizophrenia between the ages of 18-50 years.\n\nExclusion Criteria:\n\n* Current substance misuse\n* Pregnancy or breast feeding\n* Subjects with electrocardiographic abnormalities (particularly QTc prolongation)\n* Subjects with renal impairment\n* Subjects with hepatic impairment\n* Past or current neurological disorder (including stroke, brain tumor, epilepsy, Alzheimer's, Parkinson's or Huntington's disease)\n* Non-schizophrenia cause of cognitive impairment\n* Uncontrolled medical disorder that may interfere with cognition or compromise safety\n* Head trauma with loss of consciousness in the last year or any evidence of functional impairment due to and persisting after head trauma\n* Having a contraindication to MRI, including a pacemaker, defibrillator or other medical implant, other metal objects, or claustrophobia, or for having braces or other metal in the head region (likely to create an artifact on the MRI scans).\n* Significant suicidal ideation\n* Recent history of electroconvulsive therapy\n* Medication changes in the past six weeks","ALL","18 Years","50 Years",{"count":80,"type":81},20,"ESTIMATED","INTERVENTIONAL",[84],"PHASE2","The investigators aim to determine the effects of a novel drug on brain function and brain chemistry in patients with schizophrenia.",[87],"SCHIZOPHRENIA 1 (Disorder)",[89],"schizophrenia","NOT_YET_RECRUITING","2026-09-24",{"date":93,"type":94},"2026-09-30","ACTUAL",{"date":96,"type":81},"2027-01-01",{"date":98,"type":81},"2028-06-30",{"name":5,"class":6},1]